Anti-CD32 [AT130-5]

Catalogue Number: AB00287-23.0-BT-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:FcγRIIB; FcgRIIb; CD32B; CDw32; FCG2; FCGR2; FCGR2B; IGFR2; Immunoglobulin G Fc receptor II; Low affinity immunoglobulin gamma Fc region receptor II-b; MGC23887; MGC30032; RP11-5K23.6
Shipping Condition:Blue Ice
Unit(s): 1 mg
Host name: Rabbit
Clone: AT130-5
Isotype: IgG
Immunogen: The original antibody was generated by immunizing BALB/c FcγRIIB-/- mice with FcγRIIB-rat CD4 domain 3/4 fusion protein.
Application: FC, IF, WB, IHC, Blk, Stim

Additional Text

Gene Name

FCGR2B

Gene ID

14130

Uniprot ID

P08101

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.

Application Notes

The original version of this antibody (mouse IgG1) was used in various FACS, Western blot, and immunofluorescence experiments to demonstrate that, for example, interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 mAb (White et al., 2011; PMID: 21742972), and that immunotherapy targeting murine FcγRIIB is limited by mAb consumption and receptor internalization (Williams et al., 2013; PMID: 24026082). It is noted that, unlike the antagonistic anti-CD32 (clone AT128) antibody, which blocks FcγRIIB receptor phosphorylation, this agonistic anti-CD32 (clone AT130-5) has been shown to activate receptor function while blocking immune complex engagement to the inhibitory FcγRs (Vollack et al., 2017; PMID: 28492697). These differential antagonistic/agonistic anti-CD32 mAbs have been used to probe more specifically the role of CD32 in the murine FVIII-specific recall response (Vollack et al., 2017; PMID: 28492697).

Short Description

This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.